PDF《Content》

1 Financial Highlights 财务摘要

2 Corporate Profile 公司简介

3 Management Discussion and Analysis 管理层讨论及分析

5 Corporate Governance and Other Information 企业管治及其他资料

28 Review Report 审阅报告

40 Consolidated Statement of Profit or Loss and Other Comprehensive Income 综合损益及其他全面收益表

42 Consolidated Statement of Financial Position 综合财务状况表

43 Consolidated Statement of Changes in Equity 综合权益变动表

45 Condensed Consolidated Cash Flow Statement 简明综合现金流量表

47 Notes to the Unaudited Interim Financial Report 未经审核中期财务报表附注

48 Corporate Information 公司资料

73 Content 目录

2 Six months ended

30 June

2017 截至 2017年Six months ended

30 June

2016 截至 2016年Year ended

31 December 截至12月31日止年度 (RMB'

000) (人民币千元) 6月30日 止六个月 6月30日 止六个月

2016 2015

2014 Revenue 营业额 662,253 555,629 941,504 692,910 440,904 Gross profit 毛利 540,611 419,312 727,270 514,576 321,075 Profit from operations 经营溢利 360,491 268,556 460,299 339,605 205,445 Profit before taxation 除税前溢利 358,233 264,444 453,066 314,706 163,115 Profit attributable to equity shareholders of the Company 本公司权益股东 应占溢利 301,860 214,985 380,597 265,750 135,343 Basic/diluted earnings per share (RMB cent) 每股基本摊薄盈利 (人民币分)

67 48

84 79

45 Total assets 总资产 3,491,092 2,781,904 2,831,109 2,577,415 949,531 Total liabilities 总负债 580,782 489,709 373,302 434,566 672,276 Net assets 净资产 2,910,310 2,292,185 2,457,807 2,142,849 277,255 Profitability 盈利能力 Gross profit margin 毛利率 81.

6% 75.5% 77.2% 74.3% 72.8% Operating profit margin 经营溢利率 54.4% 48.3% 48.9% 49.0% 46.6% Net profit margin 净利润率 44.6% 38.7% 40.4% 38.4% 30.7%

3 YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (hereinafter referred to as the Company , with its subsidiaries, collectively referred to as the Group or we ) is one of the leading pharmaceutical manufacturing companies in China focusing on anti- virus medicine and covering the development, manufacture and sales of pharmaceutical products in three major therapeutic areas of anti-virus, endocrine and metabolic diseases as well as cardiovascular diseases. It is the domestic pharmaceutical manufacturing platform under Shenzhen HEC Industrial Development Co., Ltd. ( Shenzhen HEC Industrial ) and its subsidiaries. As at

30 June 2017, the Group has a pharmaceutical portfolio of

33 pharmaceutical products in total of which

25 products have been listed in the national reimbursement drug list. Our top five products, namely Kewei (oseltamivir phosphate) granules and capsules, Ertongshu (benzbromarone tablets), Oumeining (telmisartan tablets), Xinhaining (amlodipine besylate tablets) and Xining (cetirizine hydrochloride dispersible tablets), all ranked top positions among similar products in terms of sales in 2015, with our key product Kewei (oseltamivir phosphate) dominating the anti-influenza virus market in China. We have a sale network sprawling across China with a high market penetration level. In future, we will expand our coverage to hospitals and other medical institutions throughout China. 宜昌东阳光长江药业股份有限公司 (以下简称 「本公司」 ,连同其附属公司统称 「本集团」 或 「我们」 ) 是一家以抗病毒为核心,涵盖抗病 毒、内分泌与代谢疾病、心血管疾病三个主要 治疗领域的药品的开发、生产及销售的中国领 先制药企业,是深圳市东阳光实业发展有限公 司(「深东实」 ) 及其附属公司旗下的国内制剂平 台. 截至2017年6月30日,本集团的医药产品组合 共计33种产品,其中25种产品被列入国家医 保目录中.前五大品种,即可威 (磷酸奥司他 韦) 颗粒剂及胶囊剂、尔同舒 (苯溴马隆片) 、 欧美宁 (替米沙坦片) 、欣海宁 (苯磺酸氨氯地 平片) 、喜宁 (盐酸西替利嗪分散片) 以2015年 销售额计均跻身同类单品的前列,其核心产品 可威 (磷酸奥司他韦) 在中国抗流感病毒市场占 鞯嫉匚. 本集团的销售网络遍布全中国,市场渗透程度 深,未来将业务覆盖面拓展至全中国的医院及 其他医疗机构.